Rats and drug treatment: Adult male Wistar rats weighing 300-350 g were fed a standard diet (F-2, Funabashi Farm Co., Chiba, Japan) and water ad libitum and housed at 24°C.
The mechanism of the hypotensive effect of a-methyldopa, a widely used centrally acting antihypertensive drug, is still poorly understood.
Central adrenaline neurons whose cell bodies are located in the C1 and C2 areas of the lower brainstem (1) are known to participate in the regulation of blood pressure (2-4). Tung et al. (5)  recently reported that a-methyladrenaline (MA), a candidate for one of the in vivo metabolites of a-methyldopa, reduced blood pressure in rats when administered into the cerebral ventricle and nucleus of the solitary tract. Decrease in adrenaline contents in the rat hypothalamic nuclei was observed after five days of treatment with a-methyldopa (40 mg/kg given twice a day) (6). Thus, it is postulated that central adrenaline neurons convert a-methyldopa to MA, and the hypotensive action of a-methyldopa may be dependent on the production of MA in the central nervous system. Using a highly sensitive high-performance liquid chromatographic electrochemical de tection method for catecholamines (7-9), we quantitated a-methylated catecholamines, i.e., MA, a-methylnoradrenaline (MNA) and a-methyldopamine (MDA), as well as endogenous catecholamines in the rat brain, and we found a substantial amount of MA in the hypothalamus and C1-C2 area among the areas of the brain after the five daily treatments of a-methyldopa given twice daily, in a dose of 40 mg/kg.
Materials and Methods
Rats and drug treatment: Adult male Wistar rats weighing 300-350 g were fed a standard diet (F-2, Funabashi Farm Co., Chiba, Japan) and water ad libitum and housed at 24°C.
Alpha-methyldopa
was given orally in a dose of 40 mg/kg twice daily (9:00-10:00 am and 21 :00-22:00 pm) for five days.
Sample preparations: Four hours after the last treatment, all rats were decapitated, the brains immediately removed, and the cortex and hypothalamus dissected out by the method of Glowinski and Iversen (10). The noradrenergic Al-A2 and adrenergic C1-C2 areas in the lower brainstem were separated in accordance with the data of Chamba et al.
(11 ) on a ice-cooled glass plate. Briefly, after the removal of the cerebellum, tissue blocks were isolated from the lower brainstem by vertical cuts at 2.5 mm rostal and 2.5 mm caudal to the obex. The isolated tissues were then divided into two parts by a vertical cut of the obex. The rostal and caudal portions were labelled the C1-C2 and Al-A2 areas, respectively. The thoracic spinal cords (Th2 5) were removed by laminectomy.
All the isolated tissues were placed on dry ice and stored at -30°C until assayed.
Determination of a-methylated and endogenous catecholamines:
The catechols of the cortex, hypothalamus, spinal cord, Al-A2 and C1-C2 areas were quantitated in the homogenates pooled from 5-10 rats. Tissues were homogenized in 4 volumes of 0.4 N HCIO4, containing 3,4-dihydroxy benzylamine (DHB, 250 pg/ml) and epinine (N-methyldopamine, 50 ng/ml). Epinine was used as an internal standard for MNA, MDA, a-methyldopa, noradrenaline and dopamine, and DHB was used for MA and adrenaline. Homogenization was performed in an ice water bath for 45 sec using a Polytron homogenizer (PT 10, Kinematica, Switzer land), and homogenates were centrifuged at 15,000 rpm, 4°C for 15 min. The super natants were transferred to conical reaction vials containing 100 mg of alumina, 100 add of 0.1 M EDTA-2Na, 100 pl of 1 M sodium bisulfite and 8 ml of 3 M Tris-HCI buffer, pH 8.6. Catechols in the supernatants were absorbed onto the alumina by shaking for 30 min. After washing with 40 ml of 5.0 mM Tris-HCI buffer, pH 8.6, the alumina was transferred to a MF-1 microfilter (Bioanaly tical systems, U.S.A.). Catechols were eluted with 250 icl of 0.1 N HCIO4. Twenty ;d of the HCIO4 eluent for adrenaline and 150 111 for the other catechols were injected into the high-performance liquid chromatograph equipped with an electrochemical detector (LCEC).
The LCEC was composed of a 6000 A pump, U6K universe injector, !c-Bondapak C18 reverse phase column (30X0.39 cm), radial compression separation system (RCM 100 and Nova Pak C18 cartridge column) (Waters Assoc., U.S.A.) and an electro chemical detector (LC-4A, Bioanalytical System, U.S.A.) with a glassay carbon electrode (TL-5). The working electrode was maintained at +0.7 V versus the Ag/AgCI reference electrode. The mobile phase, 0.15 M monochloroacetic acid-NaOH buffer, pH 3.0, containing 0.2 mM sodium octylsulfate (PIC B-8, Waters Assoc.) was pumped at a rate of 0.8 ml/min at 25'C.
The concentration of each compound was calculated from the peak height ratio to the respective internal standard and compared with authentic compounds which were run through the whole sequence of procedures.
Drugs and other materials: Alpha-me thyldopa, obtained from the Merck-Banyu Co., Japan, was suspended in 0.5% carboxy methyl cellulose at a concentration of 20 mg/ ml. 
Results
The five daily treatments of a-methyldopa given twice daily in a dose of 40 mg/kg reduced systolic blood pressure significantly from 124±4 mmHg to 97±7 mmHg (n=5, P<0.01) by the tail plethysmographic method. Figure 1 shows typical chromatograms obtained from standard solutions containing known amounts of authentic noradrenaline, MNA, dopamine, a-methyldopa, epinine, MDA, adrenaline, DHB and MA. As shown in Figs. 3 and 4 , since the levels of adrenaline and MA in the brain areas were too small to quantitate with other catechols simulta neously, we used two internal standards, DHB and epinine, and applied two different sensitivities of the LCEC system. The chromatograms of B and C were illustrated at a high sensitivity, that is 20 times higher than that of the chromatogram of A. Under the conditions described in the section of Materials and Methods, noradrenaline, MNA, adrenaline, DHB, MA, dopamine, a methyldopa, epinine and MDA were eluted from a reverse phase /c-Bondapak C18 column and a Nova Pak C18 cartridge column in the LCEC system with retention times of 1 5. 7, 24.3, 26.2, 33.3, 48.4, 54.9, 67.7, 76.6 and 154.5 min, respectively. Although the separation between adrenaline and MNA was not complete, strict linearity in the standard curve for adrenaline was obtained between 2-20 picomoles per sample, and that for MA was obtained between 1-20 picomoles per sample, as indicated in the upper portion of the figure.
The chromatograms at the low sensitivity obtained from the hypothalamus and C1-C2 area of control rats (Fig. 2, control) and a methyldopa-treated rats (Fig. 2 , treated) illustrate a significant decrease of endogenous noradrenaline and dopamine. We detected a large amount of MNA and MDA in these areas. Figure 3 shows typical chromatograms of adrenaline obtained from the hypothalamus and C1-C2 area. The decreases of endoge nous adrenaline are illustrated in the chromatograms after a-methyldopa treatment. Fig. 1 . Typical chromatograms of authentic noradrenaline (NA), a-methylnoradrenaline (MNA), dopamine (DA), a-methyldopa (MDP), epinine (EPI, internal standard), a-methyldopamine (MDA), adrenaline (AD), 3,4-dihydroxybenzylamine (DHB, internal standard) and a-methyladrenaline (MA) extracted as described in "Materials and Methods".
NA, MNA, AD, DHB, MA, DA, a-methyldopa, epinine and MDA were eluted from a reverse phase u-Bondapak C18 column and a Nova Pak C,g cartridge column in the LCEC system with retention times of 15.7, 24.3, 26.2, 33.3, 48.4, 54.9, 67.7, 76 .6 and 154.5 min, respectively.
The strict linearity in calibration curves of NA, MNA, DA, MDA, a-methyldopa, AD and MA are illustrated in the upper portion of the figure. (DA), a-methyldopa (MDP), epinine (EPI, internal standard) and a-methyldopamine (MDA) extracted as described in "Materials and Methods" from the hypothalamus and C1-C2 area. The decreases of the peak height of NA and DA are illustrated in the chromatograms (treated) after the a-methyldopa treatment. Fig. 3 . Typical chromatograms of adrenaline (AD) extracted from the hypothalamus and C1-C2 area. Noradrenaline (NA), a-methylnoradrenaline (MNA), AD and 3,4-dihydroxybenzylamine (DHB, internal standard) were eluted from a reverse phase p-Bondapak Ct8 column and a Nova Pak C18 cartridge column in the LCEC system with retention times of 15.7, 24.3, 26.2 and 33.3 min, respectively. The decreases of the peak height of AD are illustrated in the chromatograms (treated) after the a-methyldopa treatment.
chromatograms in the hypothalamus and C1-C2 area. No peaks were observed at the retention time of MA in the chromatograms of control rats, and there was no splitting of the MA peak in the chromatograms (treated+ authentic MA) when known amounts of authentic MA were simultaneously injected with the HC104 eluent to the LCEC system. Thus, our LCEC system allowed for quanti tation of a trace amount of adrenaline and and C1-C2 areas of the control rats. The amount of adrenaline was only 0.7 to 0.8% of the noradrenaline content in the A1-A2 area and thoracic spinal cord. We detected a relatively larger amount of adrenaline in the hypothalamus and C1-C2 area, where the adrenaline levels were about 2.0% of those of NA. The adrenaline content in the hypothalamus and C1-C2 area decreased to 10.6% and 16.1%, respectively, after five daily doses of a-methyldopa (40 mg/kg, p.o., twice a day). Although we observed a decrease of adrenaline content in the A1-A2 area and thoracic spinal cord, the level of adrenaline was under the detection limit (<2-4 picomole/ a sample) after the a-methyldopa treatment.
The endogenous noradrenaline and dopamine in all areas studied decreased significantly. We quantitated a small amount of MA in the hypothalamus and C1-C2 area; however, the levels of MA were only 9.0% and 6.2% of the endogenous adrenaline amounts, respectively (Table 2) . Although we observed a decrease of adrenaline content in the Al A2 area and thoracic spinal cord, no peaks of MA were detected in the chromatograms of these areas. The accumulation of MNA was in proportion to the levels of endogenous noradrenaline.
It should be noted that MNA was almost the same level as the endogenous noradrenaline, whereas MDA was 3 to 8 fold higher than the endogenous dopamine (Tables 1 and 2 ). Discussion basis of our results, it seems unlikely that MA plays a significant role in reducing blood pressure. However, the present study was done on a relatively wide brain area, i.e., the hypothalamus and C1-C2 area, and the sensitivity of our LCEC method used here was limited to detect smaller amounts of MA. The sensitivity of LCEC has to be increased so that we can detect metabolites of a-methyldopa in anatomically-restricted areas, such as regions punched out by the method of Palkovits (17). Furthermore, we measured MA at only one point after the five daily doses of a-methyldopa.
Thus, until more data are obtained with regard to the precise localization and the time course of MA accumulation, the role of MA in blood pressure remains speculative.
Whereas endogenous adrenaline levels of the hypothalamus and C1-C2 area were reduced after a-methyldopa to 10.6% and 16.1%, respectively, the ratios of MA to endogenous adrenaline in these areas were 9.0% and 6.2%, respectively. This has been recently confirmed and extended (22). Thus, it could be speculated that MNA produced in the hypothalamic noradrenergic nerve endings and released to synaptic clefts might be converted to MA by postsynaptically located phenylethanolamine-N-methyl transferase, after which the MA is taken up and stored in the nerve endings of nor adrenergic neurons. Therefore, endogenous adrenaline in the hypothalamic noradrenergic nerve endings may be replaced by both MNA and MA. In addition, MNA is suggested to be a poor substrate for phenylethanolamine-N methyltransferase (23). These would explain the discrepancy between the ratios of MA and MNA to endogenous adrenaline and noradrenaline.
